Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
PMID: 29268784

Abstract

BACKGROUND: Ga-labelled prostate specific membrane antigen (PSMA) ligand PET/CT is a promising modality in primary staging (PS) and biochemical relapse (BCR) of prostate cancer (PC). However, pelvic nodes or local recurrences can be difficult to differentiate from radioactive urine. CT urography (CT-U) is an established method, which allows assessment of urological malignancies. The study presents a novel protocol of Ga-PSMA-11 PET/CT-U in PS and BCR of PC.

Authors

  • Amir Iravani
    Centre for Molecular Imaging, Department of Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Australia. amir.iravani@petermac.org.
  • Michael S Hofman
    Centre for Molecular Imaging, Department of Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Australia.
  • Tony Mulcahy
    Centre for Molecular Imaging, Department of Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Australia.
  • Scott Williams
    Sir Peter MacCallum Department of Radiation Oncology, University of Melbourne, 305 Grattan Street, Melbourne, Australia.
  • Declan Murphy
    Sir Peter MacCallum Department of Surgical Oncology, University of Melbourne, 305 Grattan Street, Melbourne, Australia.
  • Bimal K Parameswaran
    Centre for Molecular Imaging, Department of Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Australia.
  • Rodney J Hicks
    Centre for Molecular Imaging, Department of Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Australia.

Keywords

External Resources

Popular Topics
Recent Journals